Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Inclusion Criteria:

• Undergoing allogeneic hematopoietic transplant for malignant or non-malignantdisease

• English speaking

• Capable of providing informed consent

• Planned to receive follow-up at the transplant site for the first 100 days posttransplantation

• Subjects who the investigator believes can and will comply with the study protocol

Exclusion Criteria:

• Documented respiratory viral infection in the two weeks prior to enrollment

• Current or planned use of any prophylactic antiviral therapy, antibody treatments,or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir,ribavirin, amantadine)

• Known allergy to study drug components (jojoba, orange oil, coconut oil, lauricacid, benzalkonium chloride, vitamin E)

• Receiving oxygen supplementation at time of enrollment

• Active mucositis at time of enrollment

• Ongoing irritation or active infection of the squamous epithelial cell skininvolving the nose or nasal vestibule

• Daily use of nasal decontamination products or other nasal medications (e.g. nasalsteroids)

• Unable to complete study procedures (e.g. nasal swab self-testing)